Breaking News, Financial News

Financial Report: Johnson & Johnson

Revenues up 9% in the quarter

Johnson & Johnson

2Q Revenues: $17.9 billion (+9%)

2Q Earnings: $3.8 billion (+172%)

YTD Revenues: $35.4 billion (+9%)

YTD Earnings: $7.3 billion (+38%)

Comments: Worldwide Pharmaceutical sales were $7.0 billion in the quarter, up 12%, driven by sales of Remicade and Simponi, Stelara, Invega Sustenna/Xeplion, Velcade and Prezista. Domestic sales increased 9% and international sales increased 14%. Worldwide Consumer sales were $3.7 billion, up 1%. Results in the quarter included the gain on the sale of the equity interest in Elan Corp.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters